Abstract: This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

Abstract: This disclosure provides silyl lipid molecules in which one or more carbon-to-carbon double bonds in the lipophilic portion is substituted with a silicon atom. Guidance is provided by which the reader may make silyl lipid molecules from molecular building blocks, and then incorporate silyl lipid molecules into lipid nanoparticles (LNPs). The silyl LNPs can be used as carriers of pharmaceutical agents. Flexible steric and substitution patterns of silyl groups in the LNPs give the user a way to fine-tune physicochemical properties, achieving improved stability and clinical efficacy. This technology is useful for immunization or genetic therapy, such as the preparation and administration of RNA vaccines for protection against the virus that causes COVID-19.

Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.

Abstract: The present invention is directed to peptisomes, including nanopeptisomes, which have a perfluorocarbon liquid core containing a perfluorocarbon liquid and a cargo, such as a therapeutically active agent, dispersed in the perfluorocarbon. liquid, and a plurality of amphiphilic peptide molecules surrounding the perfluorocarbon liquid core, wherein the amphiphilic peptide is represented by Formula (I) HB-CL-HP wherein HB is a fluorinated hydrophobic block, such as a fluorinated hydrophobic amino acid sequence, CL is a cross-linking motif, and HP is a hydrophilic amino acid sequence. The present invention is also directed to methods of use of the amphiphilic peptides and peptisomes, such as nanopeptisomes, to deliver a cargo, such as a therapeutically active agent, to a cell, Q wherein the cell may be in vitro, ex vivo, or in vivo.

Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.

Abstract: The present invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof, which are useful for treatment of a disease, disorder, or condition such as inflammatory diseases, respiratory diseases, organ diseases, viral infections, and sequelae and associated conditions such as acute respiratory distress syndrome.

Abstract: This invention provides a mono dispersed polymeric nanogel particle consists of a plurality of hydrophilic polymers or amphiphilic copolymers crosslinked with a plurality of cyclodextrin derivatives by sulfhydryl bonds. In some embodiments, the surface of the nanogel particle are attached with functional molecules, e.g., a cancer targeting ligand and a near-infrared dye. The polymeric nanogel particle can be made in aqueous solution at room temperature without organic additives via a continuous flow droplet reaction (CFDR™) method. The nanogel particle of this invention possesses internal pores, which can be used to encapsulate suitable compounds, particularly hydrophobic compounds to form stable colloidal dispersions in aqueous solution. Aspects of this invention include a method of inhibiting cancer cell growth.

Abstract: A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compostions related to plasma dried by the methods of the present invention.

Abstract: Disclosed is a vaporization tablet including an inner core comprising a first cannabis concentrate, the first cannabis concentrate comprising terpenes, and an outer layer at least partially surrounding the inner core, the outer layer comprising at least one of THCA and CBDA.

Abstract: Components with relatively high loading of active pharmaceutical ingredients (e.g., drugs), are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent (e.g., a solid API) and a supporting material (e.g., a binder such as a polymer) such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle.

Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising levodopa.

Abstract: A method of preparing a pharmaceutical composition having a drug-containing core enclosed by one or more silicon oxide materials is provided. The method entails alternating exposing the particles to gaseous or vaporous SiCl4 and gaseous or vaporous H2O at a reduced temperature and in the absence of a catalyst.

Abstract: An antimicrobial material including a composite of a matrix component comprising a flexible hydrophilic polymer foam or fiber matrix comprising two matrix faces providing a release face and a reverse face or two release faces, and therebetween a structural matrix framework defining a network of cells having a cell network surface and therein a network of pores or cell openings, and a powder charge component comprising antimicrobial additive or wound care additive, wherein said powder charge is comprised at one said release face or both said faces and/or within said cell network.

Abstract: The invention encompasses composite materials having a fibrous core that is at least partially covered by a water-swellable coating layer in which the water-swellable coating layer includes a water-swellable polymer. The invention also encompasses methods for manufacturing such a composite material, and further encompasses articles of manufacture made from such composite materials and methods for manufacturing such articles.

Abstract: A sterilizing device includes a housing having an opening in at least one direction thereof. The housing also has a hollow portion configured to allow insertion of an object (target) including part of a human body from the opening into the hollow portion. The sterilizing device also includes at least one air blower unit configured to send a flow of air toward an interior of the hollow portion, and at least one ultraviolet light emitting unit configured to emit ultraviolet light toward the interior of the hollow portion. The ultraviolet light emitted from each ultraviolet light emitting unit includes at least part of ultraviolet light having a wavelength between 190 nm and 230 nm and at least part of ultraviolet light having a wavelength between 230 nm and 237 nm, but does not include ultraviolet light having a wavelength below 190 nm and beyond 237 nm.

Abstract: A disinfection device may include a disinfection chamber, an ozone generator configured to generate ozone, and a humidifier configured to generate humidity and configured to be fluidly coupled to the disinfection chamber and the ozone generator, the humidifier being configured to encourage a mixing of generated ozone with generated humidity.

Abstract: Devices, systems, and methods for controlling microbial contamination of scooters are disclosed. A method may include determining that a user interaction with a vehicle is complete, presenting a first indication that the vehicle is unavailable for use, activating a heating element of the vehicle, the heating element associated with a microbial reduction process, determining that a time period associated with the microbial reduction process has expired, deactivating, based on the expiration of the time period, the heating element of the vehicle, and presenting a second indication that the vehicle is available for use.

Abstract: The present invention relates to a contact lens-type dressing manufactured by using a partially cured amniotic membrane dressing and a method of manufacturing same. The method of manufacturing a partially cured contact lens-type amniotic membrane dressing, and the partially cured contact lens-type amniotic membrane dressing of the present invention have a simple manufacturing method, can produce a contact lens-type amniotic membrane without foreign matter, have excellent biocompatibility, have excellent lens compatibility such as transparency and tensile strength compared to a fully cured contact lens-type amniotic membrane dressing, and also have excellent wound healing effects, and therefore, can be effectively used for the treatment of eye diseases such as corneal damage.

Abstract: Compositions comprising perforated, unseparated amnion/chorion; perforated, separated amnion; and perforated, separated chorion derived from the placenta and methods of preparing and using those compositions are provided. Perforation of placental tissue before or during processing may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the perforated compositions of the invention to the wound.

Abstract: A pre-loadable dried biological heart valve and a preparation method thereof. The preparation method includes: Step A: soaking a fresh animal pericardium in an aqueous solution of soluble elastin or glycosaminoglycan, and then subjecting the pericardium to a first cross-linking reaction in a mixed solution of carbodiimide or N-hydroxysuccinimide to allow the soluble elastin or glycosaminoglycan to bind to the pericardium via a chemical bond; and Step B: subjecting the pericardium after the first cross-linking to a second cross-linking reaction in an aqueous glutaraldehyde solution, and then drying the pericardium after the second cross-linking, to obtain the pre-loadable dried biological heart valve. The dried biological heart valve obtained by the above preparation method has good toughness, and is rapidly flattened out in a simulated folding and pressing test.

Abstract: The present invention relates to an ovarian-derived hydrogel material, which can be useful for three-dimensional in vitro culturing of cells, cell therapy, fertility preservation, drug delivery, site-specific remodeling and repair of damaged tissue, and/or diagnostic kits.

Abstract: Cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising polyvinyl alcohol (PVA), wherein the hydrogel component has a crystallinity of 20% or greater.

Abstract: The invention provides a novel approach in which zwitterionic networks are used to sequester and deliver ionic biomolecules, such as proteins, without compromising their native conformation and bioactivity. Zwitterionic networks are designed to effectively retain and deliver ionic or polar biomolecules for guided tissue regeneration. The invention represents a conceptual advance and enables a novel strategy for the utilization of zwitterionic motifs as therapeutics delivery vehicles and tissue engineering scaffolds.

Abstract: A medical system including a tube defining a lumen, a porous body connected to a distal end of the tube to be advanced to a target site within a subject. The porous body defines a plurality of openings, the plurality of openings are in fluid connection with the lumen, the porous body includes a first material and a second material, and the second material elutes from the porous body in the subject.

Abstract: A photocatalyst for air purification, a photocatalyst film including the photocatalyst, and an air purification device including the photocatalyst. The photocatalyst for air purification includes: a first metal oxide particle having ultraviolet absorptivity, and fluorine bound to a surface of the first metal oxide particle; second metal oxide particles present on the surface of the first metal oxide particle. The use of the photocatalyst for air purification to remove or degrade volatile organic compounds (VOCs) and viruses.

Abstract: Provided are methods for preparing pathogen-inactivated platelet compositions, as well as processing sets and compositions related thereto.

Abstract: In a pump arrangement (6) for use with a double breast pump device, a first air conduit (65) and a second air conduit (66) have a function in connecting respective expression kits (2, 3) to the pump arrangement (6). Each of the air conduits (65, 66) N is connectable to and disconnectable from a suction side and a discharge side, respectively, of a pump (61) that is included in the pump arrangement (6). Further, the air conduits (65, 66) are connectable to and disconnectable from each other directly through an intermediate switching mechanism (70) arranged between the air conduits (65, 66) at a bypass position with respect to the pump (61), so that it is possible to directly transfer vacuum between the air conduits (65, 66) and to thereby support the functioning of the pump (61) which may be relatively small for that reason.

Abstract: The present disclosure pertains to medical device such as a dialysis device for performing a hemodialysis, and/or hemofiltration and/or hemodiafiltration. The medical device can include a first functional module and a second functional module, wherein an operating hours counter for counting the operating hours is provided in the first functional module, and wherein the first functional module is configured to store an operating hours value determined by the operating hours counter in a first storage of the first functional module. In some embodiments, a second storage is provided in the second functional module, wherein the second functional module is configured to store the operating hours value determined by the operating hours counter of the first functional module in the second storage.

Abstract: The present invention generally relates to hemodialysis and similar dialysis systems, including a variety of systems and methods that would make hemodialysis more efficient, easier, and/or more affordable. One aspect of the invention is generally directed to new fluid circuits for fluid flow. In one set of embodiments, a hemodialysis system may include a blood flow path and a dialysate flow path, where the dialysate flow path includes one or more of a balancing circuit, a mixing circuit, and/or a directing circuit. Preparation of dialysate by the preparation circuit, in some instances, may be decoupled from patient dialysis. In some cases, the circuits are defined, at least partially, within one or more cassettes, optionally interconnected with conduits, pumps, or the like. In one embodiment, the fluid circuit and/or the various fluid flow paths may be at least partially isolated, spatially and/or thermally, from electrical components of the hemodialysis system.

Abstract: A method to protect kidneys of a patient undergoing cardiac surgery patient including: administrating a diuretic to the patient to increase urine output of the patient during cardiac surgery, wherein the diuretic is administered during the cardiac surgery; anesthetizing the patient with a general anesthetic during the cardiac surgery; infusing an intravenous liquid into the patient during the cardiac surgery; monitoring a rate or amount of urine output of the patient during the cardiac surgery, and automatically adjusting a rate or amount of the intravenous liquid infused into the patient to achieve or exceed a target urine output during the cardiac surgery.

Abstract: The present invention relates to an apparatus for performing an automated peritoneal dialysis treatment on a patient, the apparatus comprising: a first dialysis fluid port for receiving a first dialysis fluid having a first composition, which is determined by the concentrations of a set of first dialysis fluid constituents; a dialysis fluid line system connecting the first dialysis fluid port to a patient terminal; at least one dialysis fluid pump acting on the dialysis fluid line system and configured to convey the first dialysis fluid from the first dialysis fluid port to the patient terminal; and a control unit operably connected to the at least one pump; wherein the apparatus further comprises a second dialysis fluid port for receiving a second dialysis fluid having a second composition, which is determined by the concentrations of a set of second dialysis fluid constituents.

Abstract: Systems and methods for removing carbon monoxide from whole blood are provided. In one configuration, an extracorporeal phototherapy system includes an oxygenator and a light source configured to output light and arranged to emit the light output by the light source onto at least one surface of the oxygenator. The oxygenator includes a plurality of membrane layers each having a plurality of microporous hollow fiber membranes. The plurality of microporous hollow fiber membranes each include an external surface and an internal channel. Each of the plurality of membrane layers may be rotationally offset with respect to an adjacent layer. The oxygenator further includes a gas inlet port in fluid communication with a first end of the internal channels, a gas outlet port in fluid communication a second end of the internal channels, a blood inlet port, and a blood outlet port.

Abstract: A photopheresis system (200) is disclosed, and that may be configured to execute one or more protocols. These protocols include: 1) protocols (400; 430; 460) for purging air out of a centrifuge bowl (210) used by the photopheresis system (200); 2) protocols (500; 510 550) for assessing the installation/operation of one or more pressure domes (330) used by the photopheresis system (200); and 3) protocols (580; 600; 660; 700; 740) for collecting buffy coat from blood processed by the photopheresis system (200).

Abstract: Fluid collection systems having a canister, a lid, and a liner assembly are described. The liner assembly may include a liner and a fitment assembly. The fitment assembly may be connected to the liner by a gland. The fitment assembly may be held in place by at least one of any number of features, including a bracket or other fitment support connected to the canister and/or the lid, supports integrated into the fitment itself, a snapping mechanism, or a notch in one or more of the canister and the lid that supports the fitment.

Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: Dry powder inhalers are described. The dry powder inhaler includes an air inlet, a reservoir and an airway assembly. A mouthpiece airway is connected to a first airway of the airway assembly. An airway head is attached to the airway assembly and it extends into the reservoir cavity. In certain embodiments, the airway head has a sharpened or beveled edge. At least one airway assembly opening is present in the airway assembly for connecting the reservoir cavity to the first airway. Methods for dispensing dry powder into an airway of a dry powder inhaler and inhaling dry powder from a dry powder inhaler is also disclosed. Embodiments of a dry powder inhaler having a two-stage air movement are also described.

Abstract: A dynamic output power management unit for a heating circuit of an electronic smoking device includes a heating element connected to a power source via a first switching element. The unit has at least one voltage detection device to detect voltage values at various points of the heating circuit. A controller is configured to derive a resistance of the heating element, and estimate a discharge time or a power consumption value of the power source such that an energy converted in a period of time is substantially identical to a predetermined energy conversion value for a same period of time.

Abstract: A respiratory ventilation apparatus configured to deliver a respiratory gas to a patient interface is provided. The apparatus may include a gas pressurization unit configured to generate a pressurized respiratory gas, a gas inlet port configured to introduce the respiratory gas into the respiratory ventilation apparatus, a gas outlet port configured to discharge the pressurized respiratory gas to a respiration tube, a detection module configured to detect the pressure of the pressurized respiratory gas, at least one non-volatile memory configured to store a plurality of parameters and a plurality of programs, and one or more controllers. The one or more controllers may be configured to initiate the respiratory ventilation apparatus upon a boot operation, and/or initiate a program that constantly reads information from the detection module, and controls the pressure of the pressurized respiratory gas using the information read from the detection module and at least one parameter.

Abstract: A flow generator 21 for a respiratory therapy system configured to deliver a breathable gas flow to a patient comprises a housing 27 comprising an inlet 28 and an outlet 25 and a gas flow path between the inlet 28 and outlet 25. An impeller is mounted within the housing 27 for rotation about an axis, the impeller configured to be rotationally driven by a motor to provide a gas flow along the gas flow path. Various embodiments are disclosed in which the flow generator 21 further comprises a sensor 23 mounted in the housing 27 in the gas flow path and configured to detect a property of the gas flow. The sensor 23 may be mounted in the outlet 25 so as to project into the gas flow path. Flow generator may comprise an axial inlet 28 and a tangential outlet 25. In another embodiment the sensor 23 may be mounted in the inlet 28.

Abstract: A breathing assistance device with improved pressure characteristics provides a high level of CPAP per unit of supplementary respirable gas consumed while maintaining low CPAP fluctuations throughout the breath cycle utilizing a frustrum-shaped air channel to accelerate air flow. In some embodiments, a manometer is provided for monitoring pressure and/or a pressure relief valve is provided as a safety measure against overpressure delivered to a patient. In some embodiments, the device is disposable for one-time or single patient use.

Abstract: A method for changing the effective ventilation of a mechanically ventilated subject to enable or carry out non-invasive determination of hemodynamic parameters is disclosed. The method includes a step of ventilating the subject using a ventilation pattern comprising at least one phase of increased ventilation and at least one phase of decreased ventilation, wherein the phase of decreased ventilation comprises at least one prolonged breath including a respiratory pause (IRP). The respiratory pause is initiated when the lung pressure (Palv) of the subject is between a minimum lung pressure and a maximum lung pressure of the subject during the prolonged breath.

Abstract: Technologies (e.g., devices, systems and methods) for sanitizing positive airway pressure (PAP) systems are described. In some embodiments, the technologies include a PAP delivery system comprising a hose and a PAP mask, a positive pressure supply system configured to generate a flow of pressurized air which is delivered to a user through the hose to the PAP mask of the PAP delivery system, a sanitizing system configured to sanitize one or more components of the self-sanitizing PAP system, and a PAP base unit housing, wherein one or more components of the positive pressure supply system and the sanitizing system are disposed at least partially within the PAP base unit housing.

Abstract: A system for providing continuous positive air pressure therapy is provided. The system includes a flow generator, a sensor, and a computing device. The computing device is configured to control operation of the flow generator based on sensor data. The computing device is further configured to display, on a display device, one or more questions relating to demographic and/or subjective feedback; responsive to displaying the one or more questions, receive one or more inputs indicating answers to the one or more questions; transmit the answers to a remote processing system; receive, from the remote processing system, settings determined based on the transmitted answers; and adjust control settings of the system based on the received settings.

Abstract: The present invention is a respiratory monitoring device which uses 2+ sensors to map respiratory motion in patients to interpret into a respiratory effort and severity score. The core components of the invention are contact-based sensors that measure relative motion of the chest, abdomen, and/or other key anatomical features, a processing unit which takes in the data from all sensors, an algorithm that analyzes and compares the data from each sensor to understand relative motion and interpret it into clinically-relevant information, and a display screen that shares this information with clinicians. The sensors are connected to each other and the information processing unit which shares data with the screen for display of a respiratory severity score based on analysis of Thoraco-Abdominal Asynchrony (TAA) or similar indicators of respiratory effort as measured by the sensor network and analyzed by the algorithm.

Abstract: A patient tube securement apparatus is disclosed that may be used for oral or nasal intubation of a patient. The apparatus may comprise an endotracheal tube securement apparatus for securing an endotracheal tube to a patient, the apparatus comprising a dermal patch arranged to be positioned on the skin of the patient, and at least one tube holder on the dermal patch. The apparatus may comprise a patient tube securement apparatus for securing a patient tube to a patient, the apparatus comprising a dermal patch arranged to be positioned on the skin of the patient, and at least one tube holder on the dermal patch. Examples are provided in which the tube holder is adjustably mounted on the dermal patch such that the position of the tube holder on the dermal patch can be adjusted without removing the dermal patch from the skin of the patient.

Abstract: A patient interface for sealed delivery of a flow of air at a continuously positive pressure with respect to ambient air pressure to an entrance to the patient's airways including at least entrance of a patient's nares to ameliorate sleep disordered breathing may include a seal-forming structure comprising a foam undercushion and a textile membrane for contact with the patient's face; a positioning and stabilising structure to maintain the seal-forming structure in sealing contact with an area surrounding an entrance to the patient's airways while maintaining a therapeutic pressure at the entrance to the patient's airways; and a plenum chamber pressurised at a pressure above ambient pressure in use.

Abstract: A cushion for a respiratory therapy mask for contacting the face of a user. The cushion has a textile layer and a resilient material bonded to a surface of the textile layer. The resilient material is self-supporting to define a profile of the cushion, and the cushion has an opening for communication with a breathing chamber and delivery of fluid to the user.

Abstract: A sealing arrangement for forming a seal between a patient's face and a patient interface device for use in delivering a flow of a treatment gas to the patient includes a generally planar substrate body having a first side and an opposite second side. The substrate body includes a main portion having an opening defined therethrough that is sized and configured to encompass the mouth and nose of the patient. The sealing arrangement further includes a first adhesive layer disposed on the first side of the substrate body and a second adhesive layer disposed on the second side of the substrate body. The first adhesive layer is sized and configured to adhere to the skin of the patient with a first adherence force and the second adhesive layer is sized and configured to adhere to a cushion of the patient interface device with a lesser second adherence force.

Abstract: Patient interfaces for respiratory therapy in the form of nasal interfaces or nasal masks include features that enhance or provide lateral stability of the interface. At least some of the embodiments provide multiple facial contact points or areas located in the general areas of the user's cheeks and/or upper lip. Some embodiments of the nasal interfaces provide advantageous sealing characteristics. The nasal interfaces may provide a controlled expiratory flow to reduce noise. Some embodiments include nasal pillows instead of or in addition to nasal prongs. The nasal pillows can have exhaust vents or can change in length in response to a pressure level within the nasal pillow.

Abstract: A patient interface for delivery of a supply of pressurised air or breathable gas to an entrance of a patient's airways comprising: a cushion member that includes a retaining structure and a seal-forming structure permanently connected to the retaining structure; a frame member attachable to the retaining structure; and a positioning and stabilising structure attachable to the frame member.